GLMDライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:12):

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases...

Stats
本日の出来高	24 293.00
平均出来高	213 541
時価総額	2.31M
EPS	$0 ( 2024-04-03 )
次の収益日	( $0 ) 2024-05-30
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.150
ATR14	$0.00300 (0.81%)

ボリューム相関

長: 0.03 (neutral)

短: 0.56 (weak)

Signal:(43.116) Neutral

Galmed Pharmaceuticals 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Galmed Pharmaceuticals 相関 - 通貨/商品

0.45
( neutral )

0.48
( neutral )

0.00
( neutral )

0.51
( weak )

Galmed Pharmaceuticals 財務諸表

Annual	2023
収益:	$0
総利益:	$-31 000.00 (0.00 %)
EPS:	$-2.50

FY	2023
収益:	$0
総利益:	$-31 000.00 (0.00 %)
EPS:	$-2.50

FY	2022
収益:	$0
総利益:	$-35 000.00 (0.00 %)
EPS:	$-11.08

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-1.320

Financial Reports:

No articles found.

Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol; and a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.